Even at this late date, Henry Waxman is still pushing to reduce the 12-year exclusivity period for FoB’s no longer protected by a US patent: http://drugtopics.modernmedicine.com/drugtopics/Modern+Medicine+Now/Waxman-12-year-wait-for-biosimilars-too-long/ArticleStandard/Article/detail/764154 See #msg-70191760 for related info.